Eton Pharmaceuticals Set To Dominate Orphan Drug Niche (NASDAQ:ETON)

This article was written by

My handle is the Michigan Value Investor, but everyone calls me MVI. I have a PhD in theoretical physics from UC Berkeley and worked briefly in the field before switching my interests to investing. I worked as an analyst at a billion dollar fund for several years before starting my own very small fund in 2009. During this time I have developed a group of stocks that I understand well, and I have excellent relations with management in many cases. This long standing familiarity with a select group of companies means I have a pool of investable ideas available to me where I don’t have to take time to get up to speed.

I first became interested in investing when I read an article about Warren Buffett, and my investing style reflects his teachings and those of Charlie Munger. Unlike many value investors, I am not impressed with Ben Graham as an investor.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ETON, HROW either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

#Eton #Pharmaceuticals #Set #Dominate #Orphan #Drug #Niche #NASDAQETON